Hyperopia Market Insights, Epidemiology, And Market Forecast-2030
Hyperopia Market
DelveInsight’s ‘Hyperopia Market’ report delivers an in-depth understanding of the Hyperopia , historical and forecasted epidemiology as well as the Hyperopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The Hyperopia market report provides current treatment practices, emerging drugs, Hyperopia market share of the individual therapies, current and forecasted Hyperopia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Hyperopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Hyperopia Market Outlook
Key Findings
The Hyperopia market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 1.0%. According to the estimates, the highest market size of Hyperopia is accessed in the United States followed by Japan, and Germany, in 2020.
The United States Market Outlook
In United States, the total market size of Hyperopia therapies is expected to increase at a CAGR of 1.2% during the study period (2018–2030).
EU-5 Countries: Market Outlook
In EU-5, the total market size of Hyperopia therapies is expected to increase at a CAGR of 0.8% during the study period (2018–2030).
Japan Market Outlook
The total market size of Hyperopia therapies in Japan is estimated to rise at a CAGR of 0.8%, during the study period (2018–2030).
Hyperopia Pipeline Development Activities
The drugs which are in pipeline include:
1. NVK-029: Nevakar
2. NVK-039: Nevakar
Request for sample pages @ Hyperopia Market Size
Table of contents
1.Key Insights
2.Report Introduction
3.Hyperopia Market Overview at a Glance
3.1. Market Share (%) Distribution of Hyperopia in 2018
3.2. Market Share (%) Distribution of Hyperopia in 2030
4.Executive Summary of Hyperopia
5.Epidemiology and Market Forecast Flow
6.Disease Background and Overview
6.1.Introduction
6.2 Signs and Symptoms
6.3. Classification
6.4. Causes of Hyperopia
6.5. Clinical types of hyperopia
6.6.Complications
6.7.Pathophysiology
6.8.Diagnosis
6.8.1. Testing
7.Current Treatment
7.1. Prescription lenses
7.1.1. Eyeglasses
7.1.2. Contact lenses
7.2.Refractive surgery
7.2.1. Laser-assisted in situ keratomileusis (LASIK)
7.2.2. Laser-assisted subepithelial keratectomy (LASEK)
7.2.3. Photorefractive keratectomy (PRK)
7.2.4. Conductive Keratoplasty
7.2.5. Phakic Intraocular Lens
7.2.6. Refractive Lens Exchange
7.3. Lifestyle and other home remedies
8.Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario: 7MM
8.3.1. Total Prevalent Cases of Hyperopia in the 7MM
8.3.2. Total Diagnosed Prevalent cases of Hyperopia in the 7MM
8.3.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
8.3.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
8.3.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
8.3.6. Treated cases of Hyperopia in the 7MM
8.4. The United States
8.4.1. Total Prevalent Cases of Hyperopia in the United States
8.4.2. Total Diagnosed Prevalent cases of Hyperopia in the United States
8.4.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United States
8.4.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the United States
8.4.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United States
8.4.6. Treated cases of Hyperopia in the United States
8.5.EU-5 Epidemiology
8.6.Germany
8.6.1. Total Prevalent Cases of Hyperopia in Germany
8.6.2. Total Diagnosed Prevalent cases of Hyperopia in Germany
8.6.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Germany
8.6.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Germany
8.6.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Germany
8.6.6. Treated cases of Hyperopia in Germany
8.7.France
8.7.1. Total Prevalent Cases of Hyperopia in France
8.7.2. Total Diagnosed Prevalent cases of Hyperopia in France
8.7.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in France
8.7.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in France
8.7.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in France
8.7.6. Treated cases of Hyperopia in France
8.8. Italy
8.8.1. Total Prevalent Cases of Hyperopia in Italy
8.8.2. Total Diagnosed Prevalent cases of Hyperopia in Italy
8.8.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Italy
8.8.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Italy
8.8.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Italy
8.8.6. Treated cases of Hyperopia in Italy
8.9. Spain
8.9.1. Total Prevalent Cases of Hyperopia in Spain
8.9.2. Total Diagnosed Prevalent cases of Hyperopia in Spain
8.9.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Spain
8.9.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Spain
8.9.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Spain
8.9.6. Treated cases of Hyperopia in Spain
8.10.The United Kingdom
8.10.1. Total Prevalent Cases of Hyperopia in the United Kingdom
8.10.2. Total Diagnosed Prevalent cases of Hyperopia in the United Kingdom
8.10.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
8.10.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
8.10.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
8.10.6. Treated cases of Hyperopia in the United Kingdom
8.11. Japan Epidemiology
8.11.1. Total Prevalent Cases of Hyperopia in Japan
8.11.2. Total Diagnosed Prevalent cases of Hyperopia in Japan
8.11.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Japan
8.11.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Japan
8.11.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Japan
8.11.6. Treated cases of Hyperopia in Japan
9. Patient Journey
10. Hyperopia: Seven Major Market Analysis
10.1. Key Findings
10.2. Market Outlook
10.3. 7MM Market Size
10.3.1. Total Market Size of Hyperopia in the 7MM
10.3.2. Market Size of Hyperopia by Treatment Options in the 7MM
10.4. The United States Market Size
10.4.1. Total Market Size of Hyperopia in the United States
10.4.2. Market Size of Hyperopia by Treatment Options in the United States
10.5. EU-5 Market Size
10.6. Germany
10.6.1. Total Market size of Hyperopia in Germany
10.6.2. Market Size of Hyperopia by Treatment Options in Germany
10.7. France
10.7.1. Total Market size of Hyperopia in France
10.7.2. Market Size of Hyperopia by Treatment Options in France
10.8. Italy
10.8.1. Total Market size of Hyperopia in Italy
10.8.2. Market Size of Hyperopia by Treatment Options in Italy
10.9. Spain
10.9.1. Total Market size of Hyperopia in Spain
10.9.2. Market Size of Hyperopia by Treatment Options in Spain
10.10. The United Kingdom
10.10.1. Total Market size of Hyperopia in the United Kingdom
10.10.2. Market Size of Hyperopia by Treatment Options in the United Kingdom
10.11. Japan
10.11.1. Total Market size of Hyperopia in Japan
10.11.2. Market Size of Hyperopia by Treatment Options in Japan
11. KOL Views
12. Market Access and Reimbursement
13. Market Drivers
14. Market Barriers
15. SWOT Analysis
16.Unmet Needs
17.Appendix
17.1. Bibliography
17.2. Report Methodology
18.DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
